Logo image of PBYI

PUMA BIOTECHNOLOGY INC (PBYI) Stock Fundamental Analysis

NASDAQ:PBYI - Nasdaq - US74587V1070 - Common Stock - Currency: USD

3.43  +0.1 (+3%)

After market: 3.43 0 (0%)

Fundamental Rating

5

Overall PBYI gets a fundamental rating of 5 out of 10. We evaluated PBYI against 555 industry peers in the Biotechnology industry. While PBYI has a great profitability rating, there are some minor concerns on its financial health. PBYI has a bad growth rate and is valued cheaply. These ratings would make PBYI suitable for value investing!


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

PBYI had positive earnings in the past year.
PBYI had a positive operating cash flow in the past year.
In multiple years PBYI reported negative net income over the last 5 years.
Of the past 5 years PBYI 4 years had a positive operating cash flow.
PBYI Yearly Net Income VS EBIT VS OCF VS FCFPBYI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M

1.2 Ratios

Looking at the Return On Assets, with a value of 19.40%, PBYI belongs to the top of the industry, outperforming 96.76% of the companies in the same industry.
PBYI has a better Return On Equity (39.20%) than 98.20% of its industry peers.
PBYI's Return On Invested Capital of 26.87% is amongst the best of the industry. PBYI outperforms 98.92% of its industry peers.
PBYI had an Average Return On Invested Capital over the past 3 years of 17.97%. This is above the industry average of 14.78%.
The last Return On Invested Capital (26.87%) for PBYI is above the 3 year average (17.97%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 19.4%
ROE 39.2%
ROIC 26.87%
ROA(3y)7.85%
ROA(5y)-2.77%
ROE(3y)24.42%
ROE(5y)N/A
ROIC(3y)17.97%
ROIC(5y)N/A
PBYI Yearly ROA, ROE, ROICPBYI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K

1.3 Margins

With an excellent Profit Margin value of 16.36%, PBYI belongs to the best of the industry, outperforming 94.41% of the companies in the same industry.
With an excellent Operating Margin value of 16.01%, PBYI belongs to the best of the industry, outperforming 94.95% of the companies in the same industry.
PBYI's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 72.40%, PBYI belongs to the top of the industry, outperforming 82.70% of the companies in the same industry.
PBYI's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 16.01%
PM (TTM) 16.36%
GM 72.4%
OM growth 3Y196.89%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.26%
GM growth 5Y-3.58%
PBYI Yearly Profit, Operating, Gross MarginsPBYI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

5

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so PBYI is creating value.
Compared to 1 year ago, PBYI has more shares outstanding
The number of shares outstanding for PBYI has been increased compared to 5 years ago.
PBYI has a better debt/assets ratio than last year.
PBYI Yearly Shares OutstandingPBYI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
PBYI Yearly Total Debt VS Total AssetsPBYI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

PBYI has an Altman-Z score of -6.24. This is a bad value and indicates that PBYI is not financially healthy and even has some risk of bankruptcy.
PBYI's Altman-Z score of -6.24 is on the low side compared to the rest of the industry. PBYI is outperformed by 65.41% of its industry peers.
The Debt to FCF ratio of PBYI is 1.80, which is an excellent value as it means it would take PBYI, only 1.80 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of PBYI (1.80) is better than 94.41% of its industry peers.
PBYI has a Debt/Equity ratio of 0.11. This is a healthy value indicating a solid balance between debt and equity.
PBYI's Debt to Equity ratio of 0.11 is on the low side compared to the rest of the industry. PBYI is outperformed by 66.31% of its industry peers.
Even though the debt/equity ratio score it not favorable for PBYI, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF 1.8
Altman-Z -6.24
ROIC/WACC2.87
WACC9.36%
PBYI Yearly LT Debt VS Equity VS FCFPBYI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

2.3 Liquidity

PBYI has a Current Ratio of 1.53. This is a normal value and indicates that PBYI is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of PBYI (1.53) is worse than 81.08% of its industry peers.
PBYI has a Quick Ratio of 1.43. This is a normal value and indicates that PBYI is financially healthy and should not expect problems in meeting its short term obligations.
PBYI's Quick ratio of 1.43 is on the low side compared to the rest of the industry. PBYI is outperformed by 81.44% of its industry peers.
Industry RankSector Rank
Current Ratio 1.53
Quick Ratio 1.43
PBYI Yearly Current Assets VS Current LiabilitesPBYI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2

3. Growth

3.1 Past

PBYI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 133.33%, which is quite impressive.
The Revenue has been growing slightly by 2.68% in the past year.
PBYI shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -3.28% yearly.
EPS 1Y (TTM)133.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%160%
Revenue 1Y (TTM)2.68%
Revenue growth 3Y-3.09%
Revenue growth 5Y-3.28%
Sales Q2Q%5.02%

3.2 Future

The Earnings Per Share is expected to decrease by -30.07% on average over the next years. This is quite bad
The Revenue is expected to decrease by -1.09% on average over the next years.
EPS Next Y-20.85%
EPS Next 2Y-19.11%
EPS Next 3Y-8.38%
EPS Next 5Y-30.07%
Revenue Next Year-2.74%
Revenue Next 2Y-1.59%
Revenue Next 3Y-0.56%
Revenue Next 5Y-1.09%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
PBYI Yearly Revenue VS EstimatesPBYI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
PBYI Yearly EPS VS EstimatesPBYI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 -2 -4 -6 -8

8

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 4.45 indicates a rather cheap valuation of PBYI.
98.92% of the companies in the same industry are more expensive than PBYI, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of PBYI to the average of the S&P500 Index (27.15), we can say PBYI is valued rather cheaply.
PBYI is valuated reasonably with a Price/Forward Earnings ratio of 8.59.
97.12% of the companies in the same industry are more expensive than PBYI, based on the Price/Forward Earnings ratio.
PBYI's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 21.60.
Industry RankSector Rank
PE 4.45
Fwd PE 8.59
PBYI Price Earnings VS Forward Price EarningsPBYI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, PBYI is valued cheaper than 99.46% of the companies in the same industry.
PBYI's Price/Free Cash Flow ratio is rather cheap when compared to the industry. PBYI is cheaper than 98.74% of the companies in the same industry.
Industry RankSector Rank
P/FCF 5.46
EV/EBITDA 2.11
PBYI Per share dataPBYI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4

4.3 Compensation for Growth

The excellent profitability rating of PBYI may justify a higher PE ratio.
PBYI's earnings are expected to decrease with -8.38% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-19.11%
EPS Next 3Y-8.38%

0

5. Dividend

5.1 Amount

No dividends for PBYI!.
Industry RankSector Rank
Dividend Yield N/A

PUMA BIOTECHNOLOGY INC

NASDAQ:PBYI (6/30/2025, 8:00:02 PM)

After market: 3.43 0 (0%)

3.43

+0.1 (+3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)07-30 2025-07-30
Inst Owners65.19%
Inst Owner Change18.17%
Ins Owners15.39%
Ins Owner Change4.51%
Market Cap170.27M
Analysts47.5
Price Target4.42 (28.86%)
Short Float %6.64%
Short Ratio7.67
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)333.26%
Min EPS beat(2)272.41%
Max EPS beat(2)394.12%
EPS beat(4)4
Avg EPS beat(4)178.28%
Min EPS beat(4)14.63%
Max EPS beat(4)394.12%
EPS beat(8)7
Avg EPS beat(8)170%
EPS beat(12)10
Avg EPS beat(12)263.94%
EPS beat(16)13
Avg EPS beat(16)206.37%
Revenue beat(2)2
Avg Revenue beat(2)5.8%
Min Revenue beat(2)1.23%
Max Revenue beat(2)10.36%
Revenue beat(4)4
Avg Revenue beat(4)6.65%
Min Revenue beat(4)1.23%
Max Revenue beat(4)11.71%
Revenue beat(8)6
Avg Revenue beat(8)3.23%
Revenue beat(12)10
Avg Revenue beat(12)5.39%
Revenue beat(16)11
Avg Revenue beat(16)3.94%
PT rev (1m)-21.21%
PT rev (3m)0%
EPS NQ rev (1m)-8.33%
EPS NQ rev (3m)-26.66%
EPS NY rev (1m)17.84%
EPS NY rev (3m)18.33%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.79%
Revenue NY rev (1m)0%
Revenue NY rev (3m)5.83%
Valuation
Industry RankSector Rank
PE 4.45
Fwd PE 8.59
P/S 0.73
P/FCF 5.46
P/OCF 5.44
P/B 1.75
P/tB 3.52
EV/EBITDA 2.11
EPS(TTM)0.77
EY22.45%
EPS(NY)0.4
Fwd EY11.64%
FCF(TTM)0.63
FCFY18.3%
OCF(TTM)0.63
OCFY18.37%
SpS4.69
BVpS1.96
TBVpS0.98
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 19.4%
ROE 39.2%
ROCE 34.01%
ROIC 26.87%
ROICexc 179.97%
ROICexgc N/A
OM 16.01%
PM (TTM) 16.36%
GM 72.4%
FCFM 13.39%
ROA(3y)7.85%
ROA(5y)-2.77%
ROE(3y)24.42%
ROE(5y)N/A
ROIC(3y)17.97%
ROIC(5y)N/A
ROICexc(3y)84.91%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)22.75%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3Y271.17%
ROICexc growth 5YN/A
OM growth 3Y196.89%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.26%
GM growth 5Y-3.58%
F-Score6
Asset Turnover1.19
Health
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF 1.8
Debt/EBITDA 0.22
Cap/Depr 1.02%
Cap/Sales 0.05%
Interest Coverage 3.81
Cash Conversion 64.28%
Profit Quality 81.87%
Current Ratio 1.53
Quick Ratio 1.43
Altman-Z -6.24
F-Score6
WACC9.36%
ROIC/WACC2.87
Cap/Depr(3y)62.9%
Cap/Depr(5y)77.72%
Cap/Sales(3y)2.82%
Cap/Sales(5y)3.47%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)133.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%160%
EPS Next Y-20.85%
EPS Next 2Y-19.11%
EPS Next 3Y-8.38%
EPS Next 5Y-30.07%
Revenue 1Y (TTM)2.68%
Revenue growth 3Y-3.09%
Revenue growth 5Y-3.28%
Sales Q2Q%5.02%
Revenue Next Year-2.74%
Revenue Next 2Y-1.59%
Revenue Next 3Y-0.56%
Revenue Next 5Y-1.09%
EBIT growth 1Y39.99%
EBIT growth 3Y187.73%
EBIT growth 5YN/A
EBIT Next Year45.92%
EBIT Next 3Y3.72%
EBIT Next 5YN/A
FCF growth 1Y638.29%
FCF growth 3Y23.46%
FCF growth 5Y11.98%
OCF growth 1Y128.18%
OCF growth 3Y23.52%
OCF growth 5Y11.7%